News Brief
Summary
Stock prices for Eli Lilly and Novo Nordisk fell after former President Donald Trump announced a goal to reduce the price of brand-name GLP-1 weight loss drugs to $150 per month. A government official later clarified that no formal price agreements have been made with the drugmakers.
Key Points
- Stock Impact: Eli Lilly shares fell 2%, Novo Nordisk shares fell 3%, and Hims & Hers Health stock plunged over 15%.
- Trump’s Proposal: Aiming to set a $150 monthly price for GLP-1 drugs like Ozempic, a significant reduction from current U.S. list prices.
- Official Clarification: Dr. Mehmet Oz stated that price negotiations for GLP-1 drugs have not yet been finalized.
- Market Context: A $150 price would be lower than current compounded alternatives, potentially disrupting the cash market for these drugs.
- Broader Initiative: This is part of a larger administration effort to align U.S. drug prices with those in other developed nations.
新闻简报
总结
在前总统唐纳德·特朗普宣布计划将品牌GLP-1减肥药的价格降至每月150美元后，礼来和诺和诺德的股价下跌。随后一位政府官员澄清，尚未与制药公司达成正式的价格协议。
关键点
- 股市影响：礼来股价下跌2%，诺和诺德股价下跌3%，Hims & Hers Health股价暴跌超15%。
- 特朗普的提议：计划将像Ozempic这样的GLP-1药物价格定为每月150美元，较当前美国标价大幅降低。
- 官方澄清：Mehmet Oz博士表示，GLP-1药物的价格谈判尚未最终敲定。
- 市场背景：150美元的价格将低于当前复合药物替代品的价格，可能会扰乱这些药物的现金市场。
- 更广泛的行动：这是政府旨在使美国药品价格与其他发达国家看齐的更广泛努力的一部分。
Original Article Link: https://www.cnbc.com/2025/10/17/eli-lilly-novo-nordisk-stock-trump-glp-1-prices.html